Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) EV-to-Revenue : 41.45 (As of Jun. 05, 2024)

View and export this data going back to 2008. Start your Free Trial

What is Cannabis Bioscience International Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cannabis Bioscience International Holdings's enterprise value is $5.68 Mil. Cannabis Bioscience International Holdings's Revenue for the trailing twelve months (TTM) ended in Nov. 2023 was $0.14 Mil. Therefore, Cannabis Bioscience International Holdings's EV-to-Revenue for today is 41.45.

The historical rank and industry rank for Cannabis Bioscience International Holdings's EV-to-Revenue or its related term are showing as below:

CBIH' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.08 Med: 0.08 Max: 0.09
Current: 41.45

During the past 5 years, the highest EV-to-Revenue of Cannabis Bioscience International Holdings was 0.09. The lowest was 0.08. And the median was 0.08.

CBIH's EV-to-Revenue is ranked worse than
95.7% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 2.26 vs CBIH: 41.45

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Cannabis Bioscience International Holdings's stock price is $0.0008. Cannabis Bioscience International Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Nov. 2023 was $0.00. Therefore, Cannabis Bioscience International Holdings's PS Ratio for today is .

Cannabis Bioscience International Holdings EV-to-Revenue Historical Data

The historical data trend for Cannabis Bioscience International Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannabis Bioscience International Holdings EV-to-Revenue Chart

Cannabis Bioscience International Holdings Annual Data

Trend

Dec06

Dec07

May09

May10

May11

EV-to-Revenue

0.57

0.19

Cannabis Bioscience International Holdings Semi-Annual Data
	Dec06	Jun07	Dec07	Jun08	May09	Nov09	May10	Nov10	May11	Nov11	Nov22	Nov23
EV-to-Revenue	Get a 7-Day Free Trial							0.41	0.19	0.16	113.97	145.11

Competitive Comparison of Cannabis Bioscience International Holdings's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Cannabis Bioscience International Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannabis Bioscience International Holdings's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannabis Bioscience International Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cannabis Bioscience International Holdings's EV-to-Revenue falls into.

Cannabis Bioscience International Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Cannabis Bioscience International Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	5.679	/	0.137
	=	41.45

Cannabis Bioscience International Holdings's current Enterprise Value is $5.68 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cannabis Bioscience International Holdings's Revenue for the trailing twelve months (TTM) ended in Nov. 2023 was $0.14 Mil.

Cannabis Bioscience International Holdings (OTCPK:CBIH) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Cannabis Bioscience International Holdings's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.0008	/	0
	=

Cannabis Bioscience International Holdings's share price for today is $0.0008.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Nov. 2023 was $0.00.

Cannabis Bioscience International Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cannabis Bioscience International Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannabis Bioscience International Holdings (Cannabis Bioscience International Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannabis Bioscience International Holdings Inc (OTCPK:CBIH) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

6201 Bonhomme Road, Suite 466S, Houston, TX, USA, 77036

Website

https://www.cbih.net

Cannabis Bioscience International Holdings Inc is engaged in providing educational systems relating to cannabis and services in therapeutic areas. of clinical trials and services relating to sleep disorders through its sleep center in Houston, Texas. The Company generates revenue from multiple streams, namely, clinical trials, consulting fees, video courses, seminars, royalties, and merchandise sales. The company generates the majority of its revenue from clinical trials.